Purpose: To study the relationship between smartphone use and dry eye disease (DED) in pediatric age group. Materials & methods: A prospective, quasi-experimental study of 78 children diagnosed with DED (as per International Dry Eye Workshop guidelines) was conducted at a tertiary care hospital, Odisha over the duration of 9 months from July 2016-March 2017. Questions on time of smartphone/other visual display terminal use, continuous reading hour, outdoor activity were asked to older children and parents of younger children. Symptoms were noted and the Ocular Surface Disease Index (OSDI) score calculated. Ocular examination including slit lamp, inter blink interval (IBI), tear-film breakup time (TBUT) & Schirmer's test (ST) done. The patients were divided into Category A (continuous smartphone use for >/=1hr) & Category B (use for <1hr at a stretch/intermittent use). Results: Of the 78 children (43.6% rural & 56.4% urban) 88.4% belonged to Category A and 11.6% to Category B. Mean IBI in Category A was 2.89s & in Category B it was 4.32s, mean TBUT was measured at 8.87 s and 9s in both the categories respectively, and a Schirmer's value of <10mm without anaesthesia in both the categories. Patients were reviewed again after discontinuing use of smartphone for 1 month. Improvement in symptoms and dry eye scores noted with the values being statistically significant (p<0.05). Conclusion: Smartphone use continuously for longer time can lead to symptoms of DED in children. With increasing smartphone use among younger population this is a cause of concern.

Objective: To find out outcome following single intravitreal injection of ranibizumab in branch retinal vein occlusion (BRVO) patients in a government hospital in the capital of Odisha. Methods: This study was a prospective interventional study of 18 months duration, done from August 2017 to February 2019 which included 21 cases of BRVO. Thorough history was taken and detail ophthalmological evaluation was done. Best corrected visual acuity (BCVA) was examined with Snellen's chart and central macular thickness (CMT) was measured using optical coherence tomography (OCT). Routine blood tests were done. Intravitreal injection of ranibizumab 0.5 mg in 0.05 ml was given. BCVA and CMT was measured at 1 day, 1 week, 1 month and 3 months follow up visit. Results: Mean age was 55.29 ± 16.86 yrs. Male: female ratio was 3.2:1. 33. About 3% patients presented within 1 month of onset of symptoms. Diastolic blood pressure of ≥ 90 was found in 81% patients. 90.5% showed improvement at 1 week post-operatively.At post-operative day 1 CMT was significantly decreased (p= 0.0011). Reduction in mean CMT at post-operative day 7 was >270 µ. Conclusion: Single intravitreal injection of ranibizumab 0.5 mg in 0.05 mlcauses significant increase in vision and significant reduction of central macular thickness in patients with branch retinal vein occlusion.